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General Information
All chemicals were purchased from commercial vendors and used without further purifications, unless otherwise noted. 1 H NMR spectra and 13 C NMR were recorded on Bruker 300 MHz, 500 MHz or DPX-300 NMR spectrometers. Chemical shifts are reported in parts per million referenced with respect to residual solvent (CDCl 3 = 7.26 ppm and DMSO-d 6 = 2.5 ppm) or from internal standard tetramethylsilane (TMS = 0.00 ppm). The following abbreviation was used in reporting spectra: s = singlet, d = doublet, t = triplet, q = quarter, m = multiplet, dd = doublet of doublets. High resolution mass spectra (HRMS) were recorded on Finnigan MAT95XL-T using ESI. All solvents used were of HPLC grade, unless otherwise indicated. All reactions requiring anhydrous conditions were conducted under a nitrogen or argon atmosphere in flame-dried glasswares. Dimethylformamide was dried over calcium hydride and distilled under reduced pressure. All LC profiles and mass spectra were recorded on Shimadzu LC-IT-TOF and LC-ESI systems equipped with an autosampler, using reverse-phase Phenomenex Luna 5 C 18 (2) 100 Å 50 × 3.0 mm column. Proteins were expressed in E. coli strain BL21-DE3 and purified by Ni-NTA technology. IC 50 curves were generated using the Graphpad Prism software v. 5 (GraphPad, San Diego, USA). Methyl 
Synthetic procedures for the unnatural amino acid
2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-iodophenyl) propanoate (7)
Thionyl Chloride (15 mL) was added dropwise to 4-Iodo-L-phenylalanine (12 g, 41.3 mmol, synthesized following reference 1) [1] in a methanol (200 mL) solution at 0 o C.
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155. 5, 143.6, 141.3, 137.6, 135.4, 131.2, 127.7, 127.1, 125.0, 120.0, 92.6, 66.8, 54.5, 52.4, 47.14, 37.7 . IT-TOF: m/z [M+H] + calcd: 528.06, found: 528.03. 6, 155.4, 143.7, 141.3, 136.3, 132.1, 129.1, 127.7, 127.0, 125.0, 121.9, 120.0, 104.7, 94.4, 66.9, 54.6, 52.3, 47.1, 38.1, + calcd: 520.20, found: 520.17.
Methyl 2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-((trimethylsilyl) ethynyl) phenyl)propanoate (8)
DMF
2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-ethynylphenyl)propanoic acid (9)
S4
The compound 8 (2.0 g, 4 mmol) was dissolved in MeOH (10 mL) and cooled to 0 o C. NaOH (10 mL, 10 M) was added dropwise. After 5 hours, the pH of the solution was adjusted to 8 using HCl and NaHCO 3 (sat). Then to the mixture was added Fmoc-OSu (1.6 g, 4.8 mmol) followed by stirring overnight. MeOH was removed in vacuo and the aqueous layer was extracted with EtOAc. The combined organic phases were washed with brine and dried with Na 2 SO 4 . After removal of the solvent under reduced pressure, column chromatography on silica gel (9/1 Hexane/EtOAc to 9/1 EtOAc/MeOH with 0.1 % acetic acid gradients) afforded 9 (1.07 g, 65 %) as a white solid. 1 8, 158.3, 145.2, 142.5, 139.6, 133.0, 128.7, 128.1, 126.1, 122.1, 120.9, 84.3, 78.5, 67.9, 56.5, 48.3, 38.3, 26.3 155.5, 143.8, 141.3, 136.6, 132.3, 131.2, 129.4, 127.7, 127.0, 125.0, 121.0, 120.0, 119.3, 77.3, 83.3, 66.9, 66.2, 54.6, 47.2, Ethyl 5-(4-(2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(allyloxy)-3-oxopropyl)phenyl)isoxazole-3-carboxylate (11) [2] 170.8, 159.9, 156.9, 155.5, 143.7, 141.3, 138.9, 131.1, 130.1, 127.7, 127.0, 126.0, 125.4, 125.0, 120.0, 119.4, 99.8, 66.8, 66.2, 62.2, 54.6, [3] Compound 11 (20 mg, 0.03 mmol) was dissolved in DCM under an N 2 atmosphere. Phenylsilane (8 mg, 0.07 mmol) and Pd(PPh 3 ) 4 (1.7 mg, 1.5 μmol) were added. After 30 min, the solution became slightly dark and TLC was showed the reaction was finished. The solvent was removed under reduced pressure and the residue was directly purified by flash chromatography to obtain compound 6' (89 % 1, 171.1, 159.4, 156.8, 155.9, 143.7, 141.4, 140.7, 130.1, 127.6, 127.0, 125.7, 125.2, 124.3, 120.1, 100.4, 65.6, 61.2, 55.2, 46.5, 36.3, 14.0 Figure S1 . The analytical HPLC results of compound 6'
2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-(3-(ethoxycarbonyl)isoxazol-5 -yl)phenyl)propanoic acid (6')
Procedure and LC-MS profiles of inhibitors and SH2-binding peptide
Synthesis of inhibitors
Scheme S1: Solid phase synthesis of two STAT3 PPI inhibitors. 
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Inhibitor I1. Wang resin was used to synthesize the inhibitors. First, Wang resin (100 mg, 0.05 mmol, and loading ~0.5 mmol/g) was previously swollen in DMF. Fmoc-Leu-OH (4 equiv) was pre-activated using HOBT (4 equiv), HBTU (4 equiv), DIEA (8 equiv) in DMF. And the resins were added into the solution. The reaction was shaken for 4 hours at room temperature. After that, the resin was washed with DMF (3×), DCM (3×) and DMF (3×). Next, Fmoc-protected amino functionalized resin was treated with 20% piperidine in DMF for 1 hour at room temperature. The rein was washed with DMF (3×), DCM (3×) and DMF (3×). Fmoc-Tyr (HPO 3 Bzl)-OH were pre-activated by HOBT (4 equiv), HBTU (4 equiv), DIEA (8 equiv) in DMF. The resin was added into the solution and shaken at room temperature overnight. Subsequently, the resin was washed with DMF (3×), DCM (3×) and DMF (3×). Deprotection of the Fmoc group was carried out with 2% DBU in DMF for 2 hours [4] . And the resin was washed again. 4-Cyanobenzoic acid was coupled with the resin using HOBT (4 equiv), HBTU (4 equiv), and DIEA (8 equiv) in DMF overnight. The resin was then washed with DCM and MeOH before being dried in vacuo. The cocktail cleavage solution contains TFA/TIS/DCM (95:2.5:2.5). The resin was treated with the cocktail for 2.5 hours, after which the resin was filtered off and the solvent was removed under reduced pressure. The resulting inhibitor was further purified by preparative HPLC. 
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Inhibitor I2. The inhibitor I2 was synthesized similarly as I1 following procedures as shown above. The unnatural amino acid, compound 6', was coupled to the resin as follows. First, 6' was pre-activated by HOBT (4 equiv), HBTU (4 equiv), DIEA (8 equiv) in DMF. Then resin was added into the solution and the resulting mixture was shaken at room temperature overnight. Subsequently, the resin was washed with DMF (3×), DCM (3×) and DMF (3×). The deprotection of Fmoc group was carried on 2 % DBU in DMF for 2 hours [4] . And the resin was washed again. 4-Cyanobenzoic acid was coupled with the resin using HOBT (4 equiv), HBTU (4 equiv), and DIEA (8 equiv) in DMF overnight. The resin was washed, after coupling, with DMF (3×), DCM (3×) and DMF (3×). At the end of solid phase synthesis, the resin was washed with DCM and MeOH before being dried in vacuo. The inhibitor was cleaved off the resin by treatment with the cocktail mixture, TFA/TIS/DCM (95:2.5:2.5), for 2.5 hours. After that, the resin was filtered off and the solvent was removed under reduced pressure to give the protected form of the final product (precursor). The final product was subsequently obtained by treating the precursor with LiOH (2 M) in THF for 2 hours followed by purification with preparative HPLC. 9, 171.0, 164.9, 160.8, 157.7, 141.4, 139.5, 137.9, 132.3, 130.0, 128.2, 125.6, 124.4, 118.3, 113.7, 100.4, 53.4, 50.4, 36.9, 24.3, 22.8, 21.3 Based on the 1 H NMR result, we found no sign of racemization in the final product I2, indicating that during the synthesis of the new amino acid 6' and the final inhibitor I2, the two steps where base treatments were involved (8 to 9 in Scheme 1 and the LiOH treatment of the cleaved peptide giving I2 in Scheme 2) did not cause noticeable racemization. 
Synthesis of SH2-binding peptide Fluorescein-GY*LPQTV-NH 2
Rink amide resin (100 mg, loading ~ 0.5 mmol/g) was first swollen in DMF and washed with DMF (2×). Before coupling, 20% piperidine in DMF was used to deprotect the Fmoc group for 1 h at RT. Subsequently, the resin was washed with several cylces of DMF and DCM. Fmoc-Val-OH (4 equiv) was pre-activated using HOBT (4 equiv), HBTU (4 equiv), DIEA (8 equiv) in DMF. The resin was put into the solution and shaken for 4 hours. Next, the resin was washed with several cycles of DMF and DCM and treated with 20% piperidine to remove the Fmoc group prior to the next coupling. 
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The cycle of coupling was repeated with Fmoc-Thr(OtBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Tyr(HPO 3 Bzl)-OH, Fmoc-Gly-OH. Final, the resin was coupled with 3', 6'-diacetyl fluorescein (4 equiv). After washing, the acetyl protecting group was removed by treatment with 20% piperidine in DMF. Finally, the resin was washed with DMF (3×), DCM (3×) and MeOH (3×) and dried thoroughly under reduced pressure. A solution of cleavage solution TFA/TIS/DCM (95:2.5:2.5) was added to the resin for 2 hours. The resin was filtered off. The solvent was removed in vacuo. The peptide was purified by preparative HPLC.
Procedures and results of cell proliferation
T47D cancer cell line was from the National Cancer Institute Developmental Therapeutics Program (NCI60 cell line panel). Cells were cultivated in a T25 flask in RPMI (Invitrogen, Carlsbad, CA) medium with 10% Fetal Bovine Serum (FBS, Gibco Invitrogen) and 100 U/mL Penicillin-Streptomycin (Thermo Scientific, Rockford, IL) and maintained in a humidified 37 o C incubator with 5 % CO 2 . Subsequently, trypsin with EDTA were used to detach cells detach from the flask. Cells were counted using Hemocytometer and seeded equally into each well of a 96-well plate. Each well contains around 3000~4000 cells in culture medium with 10% FBS. After overnight culture, the medium was aspirated and then treated with different concentrations of I1 and I2 in DMSO (500 μM, 250 μM, 125 μM). Staurosporine (STS) was used as a positive control. The same volume of DMSO (final concentration in each well is 0.56%) was used as a negative control. After 2 days, the tetrazolium salt XTT solution (0.2 mg/mL XTT, 25 M phenazine methosulfate (PMS), Roche) was added to the cells. After incubating at 37 o C for 20 hours, the absorbance was measured at 450 nm and background absorbance was measured at 650 nm using a Bioteck™ plate reader. Data was presented as the following: A 450nm and A 650nm are the absorbance at 450 nm and the background absorbance at 650 nm of the sample wells; a 450nm and a 650nm are the absorbance at 450nm and the background absorbance at 650nm of the control wells (which only contained DMSO).
Procedure and results of fluorescence polarization (FP) experiments
The clone containing the mammalian STAT3 SH2 domain was purchased from Open Biosystems (USA). The construct contains the SH2 domain cloned into a modified pET28 bacterial expression vector. A 6xHis tag is encoded for expression at the N-terminus which gives a final 68 KD fusion protein. The protein was expressed and purified according to protocols provided by the vendor.
[5] Figure S1 shows the coomassie gel of fractions containing the purified protein (shown as a band at the expected 68KD position). Only sufficiently pure fractions were collected and used for
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the following FP experiments. Fluorescence polarization (FP) experiments were carried out following published procedures. [6] Different concentrations of the inhibitor (1 mM -7.8 μM) were first incubated with the protein (150 nM) for 30 min. Subsequently, the fluorescently labeled STAT3 peptide (Fluorescein-GY*LPQTV-NH 2 ) was then added into each well (final conc: 10 nM). The fluorescence readings were then taken with a fluorescence plate reader (Tecan, USA) installed with 2 pairs of polarizers (λ ex : 485 ± 20 nm, λ em : 520 ± 10 nm). From the data, each IC 50 plot was generated by averaging the duplicates obtained from two independent assays. 
Procedure and results of inhibition assays of PTP1B
The inhibition of I2 to PTP1B was assayed by measuring the rate of hydrolysis of the fluorogenic substrate, 6,8-difluoromethylumbellifery phosphate (DIFMUP, Invitrogen, USA) in 25 μL reaction volumes in black polypropylene flat-bottom 384-well microtiter plates (Greiner, Germany). Briefly, a two-fold dilution series of I2, from approximately 2 mM to 125 μL (final concentrations) was prepared. PTP1B's concentration is the same as STAT3 SH2 domain, 150 nM. The substrate concentration is 25 μM. The results are shown in Figure S5 . and treated I2 (bottom). where dQ/dt is the permeability rate, C 0 is the initial concentration in the donor compartment, and A is the surface area of the filter. Permeability rates were calculated by plotting the percent of initial AP drug mass (peak area) found in the BL compartment versus time and determining the slope of the line. Lucifer yellow (LY) results were used as an internal control for each monolayer to verify tight junction integrity during the entire assay period. Accordingly, LY P app values were quantified from 60 min basolateral samples after background subtraction. As a quality control, results from MDCK monolayer with LY Papp > 30 nm/s were not used. The results are shown in Table S1 , indicating I2 is indeed reasonable cell-permeable. 
Procedure and results of cell permibility test
